Oliver Brooks

1.7k total citations · 2 hit papers
17 papers, 636 citations indexed

About

Oliver Brooks is a scholar working on Infectious Diseases, Health and Epidemiology. According to data from OpenAlex, Oliver Brooks has authored 17 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Health and 4 papers in Epidemiology. Recurrent topics in Oliver Brooks's work include SARS-CoV-2 and COVID-19 Research (9 papers), Vaccine Coverage and Hesitancy (9 papers) and Viral gastroenteritis research and epidemiology (5 papers). Oliver Brooks is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (9 papers), Vaccine Coverage and Hesitancy (9 papers) and Viral gastroenteritis research and epidemiology (5 papers). Oliver Brooks collaborates with scholars based in United States, South Africa and Canada. Oliver Brooks's co-authors include Katherine E. Fleming-Dutra, Lauren E. Roper, Jefferson M. Jones, Danielle Moulia, Meredith McMorrow, Sarah S. Long, Barbara E. Mahon, Pablo J. Sánchez, Camille N. Kotton and Mila M. Prill and has published in prestigious journals such as New England Journal of Medicine, JAMA and Clinical Infectious Diseases.

In The Last Decade

Oliver Brooks

16 papers receiving 600 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

2023 171 citations Jefferson M. Jones, Katherine E. Fleming-Dutra et al. MMWR Morbidity and Mortality Weekly Report profile →
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

2023 144 citations Katherine E. Fleming-Dutra, Jefferson M. Jones et al. MMWR Morbidity and Mortality Weekly Report profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Brooks United States	10	339	311	177	119	73	17	636
Lauren E. Roper United States	11	566 1.7×	361 1.2×	175 1.0×	184 1.5×	67 0.9×	14	825
Monica Godfrey United States	9	226 0.7×	220 0.7×	126 0.7×	58 0.5×	34 0.5×	11	431
Silvia Pérez-Vilar United States	15	341 1.0×	175 0.6×	117 0.7×	51 0.4×	61 0.8×	39	586
Mary Sinnathamby United Kingdom	15	366 1.1×	551 1.8×	159 0.9×	52 0.4×	52 0.7×	28	959
Elif Alyanak United States	7	637 1.9×	236 0.8×	286 1.6×	34 0.3×	19 0.3×	8	822
Manika Suryadevara United States	15	413 1.2×	157 0.5×	242 1.4×	92 0.8×	61 0.8×	44	612
Lisa McHugh Australia	15	288 0.8×	79 0.3×	110 0.6×	41 0.3×	43 0.6×	38	589
Margrethe Greve‐Isdahl Norway	13	228 0.7×	199 0.6×	96 0.5×	39 0.3×	37 0.5×	34	583
Bahaa Abu Raya Israel	10	402 1.2×	137 0.4×	142 0.8×	71 0.6×	28 0.4×	13	526
Mohammad Hossein Razizadeh Iran	11	117 0.3×	347 1.1×	142 0.8×	23 0.2×	55 0.8×	35	701

Countries citing papers authored by Oliver Brooks

Since Specialization

Citations

This map shows the geographic impact of Oliver Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Brooks more than expected).

Fields of papers citing papers by Oliver Brooks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Brooks. The network helps show where Oliver Brooks may publish in the future.

Co-authorship network of co-authors of Oliver Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Brooks. A scholar is included among the top collaborators of Oliver Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Brooks. Oliver Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Brooks, Oliver, et al.. (2026). The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025. Clinical Infectious Diseases.

Chu, Helen Y., Noel T. Brewer, Edwin J. Asturias, et al.. (2025). The Path Forward for Vaccine Policy in the United States. New England Journal of Medicine. 393(8). 817–822. 2 indexed citations

Asturias, Edwin J., Noel T. Brewer, Oliver Brooks, et al.. (2025). Advisory Committee on Immunization Practices at a Crossroads. JAMA. 334(8). 667–667. 9 indexed citations

Moulia, Danielle, Ruth Link‐Gelles, Helen Y. Chu, et al.. (2025). Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025. MMWR Morbidity and Mortality Weekly Report. 74(32). 508–514. 2 indexed citations

Panagiotakopoulos, Lakshmi, Monica Godfrey, Danielle Moulia, et al.. (2024). Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morbidity and Mortality Weekly Report. 73(16). 377–381. 18 indexed citations

Panagiotakopoulos, Lakshmi, Danielle Moulia, Monica Godfrey, et al.. (2024). Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025. MMWR Morbidity and Mortality Weekly Report. 73(37). 819–824. 29 indexed citations

Roper, Lauren E., Monica Godfrey, Ruth Link‐Gelles, et al.. (2024). Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morbidity and Mortality Weekly Report. 73(49). 1118–1123. 8 indexed citations

Fleming-Dutra, Katherine E., Jefferson M. Jones, Lauren E. Roper, et al.. (2023). Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morbidity and Mortality Weekly Report. 72(41). 1115–1122. 144 indexed citations breakdown →

Clark, Thomas A., et al.. (2023). Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morbidity and Mortality Weekly Report. 72(49). 1327–1330. 11 indexed citations

10.

Jones, Jefferson M., Katherine E. Fleming-Dutra, Mila M. Prill, et al.. (2023). Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morbidity and Mortality Weekly Report. 72(34). 920–925. 171 indexed citations breakdown →

11.

Rosenblum, Hannah G., Megan J. Wallace, Monica Godfrey, et al.. (2022). Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022. MMWR Morbidity and Mortality Weekly Report. 71(45). 1436–1441. 86 indexed citations

12.

Twentyman, Evelyn, Megan J. Wallace, Lauren E. Roper, et al.. (2022). Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022. MMWR Morbidity and Mortality Weekly Report. 71(31). 988–992. 18 indexed citations

13.

McDougle, Leon, Dial Hewlett, Sonja S. Hutchins, et al.. (2021). Serving as Trusted Messengers about COVID-19 Vaccines and Therapeutics. Journal of the National Medical Association. 113(1). 6–7. 7 indexed citations

14.

Dooling, Kathleen, Julia W. Gargano, Danielle Moulia, et al.. (2021). Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021. MMWR Morbidity and Mortality Weekly Report. 70(38). 1344–1348. 25 indexed citations

15.

Woodworth, Kate R., Danielle Moulia, Jennifer P. Collins, et al.. (2021). The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021. MMWR Morbidity and Mortality Weekly Report. 70(45). 1579–1583. 98 indexed citations

16.

Brooks, Oliver. (2020). What If They Threw A Pandemic And Nobody Came?. Journal of the National Medical Association. 112(2). 115–116. 3 indexed citations

17.

Brooks, Oliver. (2020). Police Brutality and Blacks: An American Immune System Disorder. Journal of the National Medical Association. 112(3). 239–241. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact